Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Yang, Ming ^a   Lai, Huafang ^a   Sun, Haiyan ^a   Chen, Qiang ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL; CELLULAR IMMUNITY; CHEMISTRY; DENGUE VIRUS; DISEASE MODEL; GENE EXPRESSION; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; MOUSE; PROTEIN DOMAIN; TOBACCO; VIROLOGY; ZIKA FEVER; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE VIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEPATITIS B VIRUS; IMMUNITY, CELLULAR; MICE; PROTEIN DOMAINS; TOBACCO; VIRAL ENVELOPE PROTEINS; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85027223330     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-08247-9     Document Type: Article

References (53)

1. Attar, N. ZIKA virus circulates in new regions. Nat Rev Micro 14, 62-62 (2016).
2. Cao-Lormeau, V.-M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet 387, 1531-1539 (2016).
3. Samarasekera, U. & Triunfol, M. Concern over Zika virus grips the world. The Lancet 387, 521-524 (2016).
4. Lazear, H. M. & Diamond, M. S. Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere. J. Virol 90, 4864-4875 (2016).
5. Dai, L. et al. Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host and Microbe 19, 696-704 (2016).
6. Zhao, H. et al. Structural Basis of Zika Virus-Specific Antibody Protection. Cell 166, 1016-1027 (2016).
7. Belmusto-Worn, V. E. et al. Randomized, double-blind, phase III. Pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in healthy infants and children in Peru. American Journal of Tropical Medicine and Hygiene 72, 189-197 (2005).
8. Heinz, F. X., Holzmann, H., Essl, A. & Kundi, M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25, 7559-7567 (2007).
9. Halstead, S.B. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology spectrum 2 (2014).
10. Morens, D. M. Antibody-dependent of enhancement of infection and the pathogenesis of viral disease. Clin Inf Dis 19, 500-512 (1994).
11. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol advance online publication (2016).
12. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823 (2016).
13. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474-478 (2016).
14. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129 (2016).
15. Pardi, N. & Weissman, D. In RNA Vaccines: Methods and Protocols. (eds. T. Kramps & K. Elbers) 109-121 (Springer New York, New York, NY; 2017).
16. Giritch, A. et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl. Acad. Sci. USA 103, 14701-14706 (2006).
17. Huang, Z., Chen, Q., Hjelm, B., Arntzen, C. & Mason, H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol Bioeng 103, 706-714 (2009).
18. Lai, H. et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc. Natl. Acad. Sci. USA 107, 2419-2424 (2010).
19. Crill, W. D. & Chang, G. J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol 78, 13975-13986 (2004).
20. He, J. et al. A Plant-Produced Antigen Elicits Potent Immune Responses against West Nile Virus in Mice. Biomed Res Int 2014, 10 (2014).
21. Oliphant, T. et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Medicine 11, 522-530 (2005).
22. Sukupolvi-Petty, S. et al. Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2. J. Virol. 84, 9227-9239 (2010).
23. Phoolcharoen, W. et al. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc. Natl. Acad. Sci. USA 108, 20695-20700 (2011).
24. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity 33, 492-503 (2010).
25. Suthar, M. S., Aguirre, S. & Fernandez-Sesma, A. Innate Immune Sensing of Flaviviruses. PLOS Pathogens 9, e1003541 (2013).
26. Saito, Y. et al. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infectious Diseases 16, 578 (2016).
27. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
28. Sirohi, D. et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352, 467-470 (2016).
29. Beltramello, M. et al. The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity. Cell host & microbe 8, 271-283 (2010).
30. Lin, H. E. et al. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis 6, e1447 (2012).
31. Whitacre, D. C., Lee, B. O. & Milich, D. R. Use of hepadnavirus core proteins as vaccine platforms. Expert Review of Vaccines 8, 1565-1573 (2009).
32. Ulrich, R., Nassal, M., Meisel, H. & Kruger, D. H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50, 141-182 (1998).
33. Brown, A. L. et al. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. Vaccine 9, 595-601 (1991).
34. Schodel, F. et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 180, 1037-1046 (1994).
35. Ruedl, C. et al. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79, 717-724 (2005).
36. Chu, X. et al. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model. International Journal of Nanomedicine 11, 2417-2429 (2016).
37. Billaud, J. N. et al. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 25, 1593-1606 (2007).
38. Chen, Q. & Davis, K. The potential of plants as a system for the development and production of human biologics F1000Research 5, doi: 10.12688/f11000research.18010.12681 (2016).
39. Tuse, D., Tu, T. & McDonald, K. Manufacturing Economics of Plant-Made Biologics: Case Studies in Therapeutic and Industrial Enzymes. Biomed Res Int 2014, 10 (2014).
40. Nandi, S. et al. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. mAbs 8, 1456-1466 (2016).
41. Lai, H. & Chen, Q. Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Reports 31, 573-584 (2012).
42. He, J., Lai, H., Brock, C. & Chen, Q. A Novel System for Rapid and Cost-Effective Production of Detection and Diagnostic Reagents of West Nile Virus in Plants. Journal of Biomedicine and Biotechnology 2012, 1-10 (2012).
43. Santi, L. et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26, 1846-1854 (2008).
44. Leuzinger, K. et al. Efficient Agroinfiltration of Plants for High-level Transient Expression of Recombinant Proteins. Journal of Visualized Experiments. doi: 10.3791/50521 (2013).
45. Chen, Q. et al. Agroinfiltration as an Effective and Scalable Strategy of Gene Delivery for Production of Pharmaceutical Proteins. Advanced Technolgy in Biology and Medicine 1, 103-112 (2013).
46. Chen, Q. In Molecular Vaccines, Vol. 1. (ed. M. Giese) 153-181 (Springer, doi: 10.1007/978-3-7091-1419-3-8, Vienna; 2013).
47. Yang, M., Dent, M., Lai, H., Sun, H. & Chen, Q. Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine 35, 4287-4294 (2017).
48. Fulton, A., Lai, H., Chen, Q. & Zhang, C. Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana. Journal of Chromatography A 1389, 128-132 (2015).
49. Lai, H., He, J., Engle, M., Diamond, M. S. & Chen, Q. Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnology Journal 10, 95-104 (2012).
50. He, J. et al. Generation and Analysis of Novel Plant-Derived Antibody-Based Therapeutic Molecules against West Nile Virus. PLoS ONE 9, e93541 doi:93510.91371/journal.pone.0093541 (2014).
51. Chen, Q. & Lai, H. Plant-derived virus-like particles as vaccines. Human Vaccines & Immunotherapeutics 9, 26-49 (2013).
52. Chen, Q., He, J., Phoolcharoen, W. & Mason, H. S. Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Hum Vaccin 7, 331-338 (2011).
53. Dent, M. et al. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J Gen Virol 97, 3280-3290 (2016).